One of Mer­ck­'s piv­otal stom­ach can­cer tri­als for Keytru­da flops, just months af­ter an FDA OK

Less than three months af­ter Mer­ck $MRK won an ac­cel­er­at­ed OK to mar­ket Keytru­da as a third-line drug for stom­ach can­cer, the phar­ma gi­ant says their check­point failed to pro­duce ei­ther pos­i­tive over­all sur­vival da­ta or pro­gres­sion-free sur­vival re­sults for the same in­di­ca­tion in a sec­ond-line set­ting.

The piv­otal Phase III flop for ad­vanced gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma marks the lat­est in a long string of of­ten sur­pris­ing hits and miss­es in the check­point field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA